A reappraisal of polymyxin B dosing based on population pharmacokinetic model in patient with renal insufficiency

2020-01-28 pharmacology and therapeutics Title + abstract only

Show abstract

BackgroundCurrent FDA-approved label recommends polymyxin B dosing should be adjusted according to renal function, despite several studies proved poor correlation between polymyxin B PK and creatinine clearance. The study aims to assess the impact of renal function on polymyxin B metabolism and identify an alternate dosing strategy by population analysis. MethodsBlood samples from adult patients were collected at steady state during routine therapeutic drug monitoring. Nonlinear mixed effects m...

A reappraisal of polymyxin B dosing based on population pharmacokinetic model in patient with renal insufficiency

Predicted journal destinations